Viridian Therapeutics, Inc.\DE
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | $284.00K | $-1.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | Before market open | $141.00K | $-0.90 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | $132.00K | $-1.08 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $70.57M | $-0.34 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $86.00K | $-1.15 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | $72.00K | $-1.02 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | During market hours | – | – | – |
Press releases
Announcements Viridian Therapeutics, Inc.\DE filed with the SEC
Viridian Therapeutics Highlights Recent Business Progress and Reports Second
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical
Regulation FD disclosure · EX-99.1 to Form 8-K
Cautionary note regarding forward-looking statements This presentation
Regulation FD disclosure · EX-99.2 to Form 8-K
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease
Regulation FD disclosure · EX-99.1 to Form 8-K
forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,”
Regulation FD disclosure · EX-99.2 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug
Regulation FD disclosure · EX-99.1 to Form 8-K
THRIVE in Active TED 52-Week Follow-Up
Regulation FD disclosure · EX-99.2 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Viridian Therapeutics Announces Positive Topline Results from Veligrotug
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
Regulation FD disclosure · EX-99.1 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
“continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating
Regulation FD disclosure · EX-99.1 to Form 8-K
VRDN-001 Phase 1/2 results in patients
Regulation FD disclosure · EX-99.2 to Form 8-K
Viridian Therapeutics Reports First Quarter 2023 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
Viridian Appoints Scott Myers as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in
Regulation FD disclosure · EX-99.1 to Form 8-K
VRDN-001 3 mg/kg results in patients
Regulation FD disclosure · EX-99.2 to Form 8-K
VIRIDIAN THERAPEUTICS REPORTS SECOND QUARTER 2022
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
data from the ongoing Phase 1/2 clinical trial of VRDN-001 and the first-in-human Phase 1 clinical trial of VRDN-002 and results of future of ongoing clinical trials; the timing, progress and plans for our ongoing and future research and clinical
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
data from the ongoing Phase 1/2 clinical trial of VRDN-001 and the first-in-human Phase 1 clinical trial of VRDN-002 and results of future of ongoing clinical trials; the timing, progress and plans for our ongoing and future research and clinical
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K